Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, Francesca Patriarca, Elena Zamagni, Daniela Donnarumma, Claudia Crippa, Mario Boccadoro, Giulia Perrone, Antonietta Falcone, Chiara Nozzoli, Renato Zambello, Luciano Masini, Anna Furlan, Annamaria Brioli, Daniele Derudas, Stelvio Ballanti, Maria Laura Dessanti, Valerio De Stefano, Angelo Michele CarellaMagda Marcatti, Andrea Nozza, Felicetto Ferrara, Vincenzo Callea, Catello Califano, Annalisa Pezzi, Anna Baraldi, Mariella Grasso, Pellegrino Musto, Antonio Palumbo

Research output: Contribution to journalArticle

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Original languageEnglish
Pages (from-to)9-19
Number of pages11
JournalBlood
Volume120
Issue number1
DOIs
Publication statusPublished - Jul 5 2012

Fingerprint

Thalidomide
Hematopoietic Stem Cell Transplantation
Stem cells
Multiple Myeloma
Consolidation
Dexamethasone
Therapeutics
Disease-Free Survival
Bortezomib
Intention to Treat Analysis
Autologous Transplantation
Stem Cell Transplantation
Peripheral Nervous System Diseases

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. / Cavo, Michele; Pantani, Lucia; Petrucci, Maria Teresa; Patriarca, Francesca; Zamagni, Elena; Donnarumma, Daniela; Crippa, Claudia; Boccadoro, Mario; Perrone, Giulia; Falcone, Antonietta; Nozzoli, Chiara; Zambello, Renato; Masini, Luciano; Furlan, Anna; Brioli, Annamaria; Derudas, Daniele; Ballanti, Stelvio; Dessanti, Maria Laura; De Stefano, Valerio; Carella, Angelo Michele; Marcatti, Magda; Nozza, Andrea; Ferrara, Felicetto; Callea, Vincenzo; Califano, Catello; Pezzi, Annalisa; Baraldi, Anna; Grasso, Mariella; Musto, Pellegrino; Palumbo, Antonio.

In: Blood, Vol. 120, No. 1, 05.07.2012, p. 9-19.

Research output: Contribution to journalArticle

Cavo, M, Pantani, L, Petrucci, MT, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, ML, De Stefano, V, Carella, AM, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P & Palumbo, A 2012, 'Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma', Blood, vol. 120, no. 1, pp. 9-19. https://doi.org/10.1182/blood-2012-02-408898
Cavo, Michele ; Pantani, Lucia ; Petrucci, Maria Teresa ; Patriarca, Francesca ; Zamagni, Elena ; Donnarumma, Daniela ; Crippa, Claudia ; Boccadoro, Mario ; Perrone, Giulia ; Falcone, Antonietta ; Nozzoli, Chiara ; Zambello, Renato ; Masini, Luciano ; Furlan, Anna ; Brioli, Annamaria ; Derudas, Daniele ; Ballanti, Stelvio ; Dessanti, Maria Laura ; De Stefano, Valerio ; Carella, Angelo Michele ; Marcatti, Magda ; Nozza, Andrea ; Ferrara, Felicetto ; Callea, Vincenzo ; Califano, Catello ; Pezzi, Annalisa ; Baraldi, Anna ; Grasso, Mariella ; Musto, Pellegrino ; Palumbo, Antonio. / Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. In: Blood. 2012 ; Vol. 120, No. 1. pp. 9-19.
@article{164b2fc735834b9d916ed86e5edd341e,
title = "Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma",
abstract = "In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1{\%}) and TD arms (54.7{\%}). After consolidation, CR (60.6{\%} vs 46.6{\%}) and CR/nCR (73.1{\%} vs 60.9{\%}) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60{\%} vs 48{\%} for TD). Grade 2 or 3 peripheral neuropathy (8.1{\%} vs 2.4{\%}) was more frequent with VTD (grade 3, 0.6{\%}) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.",
author = "Michele Cavo and Lucia Pantani and Petrucci, {Maria Teresa} and Francesca Patriarca and Elena Zamagni and Daniela Donnarumma and Claudia Crippa and Mario Boccadoro and Giulia Perrone and Antonietta Falcone and Chiara Nozzoli and Renato Zambello and Luciano Masini and Anna Furlan and Annamaria Brioli and Daniele Derudas and Stelvio Ballanti and Dessanti, {Maria Laura} and {De Stefano}, Valerio and Carella, {Angelo Michele} and Magda Marcatti and Andrea Nozza and Felicetto Ferrara and Vincenzo Callea and Catello Califano and Annalisa Pezzi and Anna Baraldi and Mariella Grasso and Pellegrino Musto and Antonio Palumbo",
year = "2012",
month = "7",
day = "5",
doi = "10.1182/blood-2012-02-408898",
language = "English",
volume = "120",
pages = "9--19",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

AU - Cavo, Michele

AU - Pantani, Lucia

AU - Petrucci, Maria Teresa

AU - Patriarca, Francesca

AU - Zamagni, Elena

AU - Donnarumma, Daniela

AU - Crippa, Claudia

AU - Boccadoro, Mario

AU - Perrone, Giulia

AU - Falcone, Antonietta

AU - Nozzoli, Chiara

AU - Zambello, Renato

AU - Masini, Luciano

AU - Furlan, Anna

AU - Brioli, Annamaria

AU - Derudas, Daniele

AU - Ballanti, Stelvio

AU - Dessanti, Maria Laura

AU - De Stefano, Valerio

AU - Carella, Angelo Michele

AU - Marcatti, Magda

AU - Nozza, Andrea

AU - Ferrara, Felicetto

AU - Callea, Vincenzo

AU - Califano, Catello

AU - Pezzi, Annalisa

AU - Baraldi, Anna

AU - Grasso, Mariella

AU - Musto, Pellegrino

AU - Palumbo, Antonio

PY - 2012/7/5

Y1 - 2012/7/5

N2 - In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

AB - In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

UR - http://www.scopus.com/inward/record.url?scp=84863576232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863576232&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-02-408898

DO - 10.1182/blood-2012-02-408898

M3 - Article

C2 - 22498745

AN - SCOPUS:84863576232

VL - 120

SP - 9

EP - 19

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -